Premium
Outbreak of vancomycin‐resistant Enterococcus faecium in a haematology unit: risk factor assessment and successful control of the epidemic
Author(s) -
Timmers Gert Jan,
Van Der Zwet Wil C.,
SimoonsSmit Ina M.,
Savelkoul Paul H. M.,
Meester Helena H. M.,
VandenbrouckeGrauls Christina M. J. E.,
Huijgens Peter C.
Publication year - 2002
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.0007-1048.2002.03339.x
Subject(s) - medicine , odds ratio , enterococcus faecium , outbreak , infection control , intensive care unit , confidence interval , risk factor , vancomycin resistant enterococcus , linezolid , enterococcus , vancomycin , intensive care medicine , antibiotics , microbiology and biotechnology , virology , biology , staphylococcus aureus , genetics , bacteria
Summary. We describe an outbreak of vancomycin‐resistant Enterococcus faecium (VRE) on the haematology ward of a Dutch university hospital. After the occurrence of three consecutive cases of bacteraemia with VRE, strains were genotyped and found to be identical. During the next 4 months an intensive surveillance programme identified 21 additional patients to be colonized with VRE, while two more patients developed bacteraemia. A case–control study was carried out to identify risk factors for VRE acquisition. In comparison with VRE‐negative control patients ( n =49), cases ( n =24) had a longer stay on the ward during the year preceding the outbreak (25·8 versus 10·1 d, P =0·02), more cases with acute myeloid leukaemia [11 versus 4, odds ratio (OR) 9·5, 95% confidence interval (CI 95 ) 2·4–32·2] and higher grades of mucositis ( P =0·03). Logistic regression analysis identified antibiotic use within 1 month before admission (OR 13·0, CI 95 2·1–80·5, P= 0·006) and low albumin levels at baseline (OR 1·2, CI 95 1·1–1·3, P =0·02) to be independent risk factors. Four patients with VRE‐bacteraemia were successfully treated with quinupristin/dalfopristin (Synercid ® ). Control of the outbreak was achieved by step‐wise implementation of intensive infection control measures, which included the cohorting of patients, allocation of nurses and reinforcement of hand hygiene.